CPSE:NOVO BPharmaceuticals
CHMP Backs Oral And High Dose Wegovy In Key Test For Novo
CHMP has issued a positive opinion for Novo Nordisk’s (CPSE:NOVO B) oral Wegovy pill, 25 mg semaglutide, for adult obesity in the EU.
The committee also backed a higher dose Wegovy 7.2 mg single dose injection pen for weight management.
Wegovy pill would be the first oral GLP 1 obesity treatment in the EU if the European Commission grants approval.
The opinion is based on data from the OASIS and SELECT trials, which assessed weight loss and major adverse cardiovascular events.
Launches are...